Patents by Inventor Mark E. Flanagan
Mark E. Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190382387Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: August 8, 2019Publication date: December 19, 2019Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Publication number: 20190119255Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: December 14, 2018Publication date: April 25, 2019Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Patent number: 10208019Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: GrantFiled: December 13, 2017Date of Patent: February 19, 2019Assignee: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Publication number: 20180170908Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: December 13, 2017Publication date: June 21, 2018Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Patent number: 7842699Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: August 28, 2009Date of Patent: November 30, 2010Assignee: Pfizer Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7803805Abstract: This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3 -oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.Type: GrantFiled: January 10, 2005Date of Patent: September 28, 2010Assignee: Pfizer Inc.Inventors: Mark E. Flanagan, Zheng J. Li
-
Patent number: 7687507Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: February 23, 2005Date of Patent: March 30, 2010Assignees: Pfizer Inc., Pfizer Products Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown
-
Publication number: 20100035903Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: ApplicationFiled: August 28, 2009Publication date: February 11, 2010Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7601727Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: July 27, 2007Date of Patent: October 13, 2009Assignee: Pfizer, Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7569569Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type 1 diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: August 13, 2003Date of Patent: August 4, 2009Assignee: Pfizer Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
-
Patent number: 7462600Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.Type: GrantFiled: December 21, 2005Date of Patent: December 9, 2008Assignee: Pfizer IncInventors: Louis S. Chupak, Mark E. Flanagan, Takushi Kaneko, Thomas V. Magee, Mark C. Noe, Usa Reilly
-
Publication number: 20080293646Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of Formula (I).Type: ApplicationFiled: March 12, 2008Publication date: November 27, 2008Inventors: Thomas V. Magee, Usa Reilly, Mark Carl Noe, Mark E. Flanagan, Zhengong Bryan Li, Richard Allen Buzon, Daniel William Widlicka
-
Patent number: 7432370Abstract: The present application discloses compounds of the formula wherein R2 and R3 are as defined herein. The present application further discloses certain pyrrolol[2,3-d]pyrimidine compounds having the 3R,4R stereochemical configuration shown above. Corresponding pharmaceutical compositions and methods for the treatment or prevention of a disorder or condition selected from organ transplant rejection, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia and other autoimmune diseases are also disclosed.Type: GrantFiled: June 15, 2004Date of Patent: October 7, 2008Assignee: Pfizer Inc.Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
-
Patent number: 7301023Abstract: A method for resolving enantiomers of a compound containing the structure of the forula: wherein R4 or R5 may contan one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined sterospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in sterospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution.Type: GrantFiled: May 23, 2002Date of Patent: November 27, 2007Assignee: Pfizer Inc.Inventors: Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7265221Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: June 23, 2006Date of Patent: September 4, 2007Assignee: Pfizer, Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7192963Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.Type: GrantFiled: April 21, 2005Date of Patent: March 20, 2007Assignee: Pfizer IncInventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 7091208Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: August 24, 2005Date of Patent: August 15, 2006Assignee: Pfizer Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: 6965027Abstract: This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.Type: GrantFiled: December 4, 2002Date of Patent: November 15, 2005Assignee: Pfizer Inc.Inventors: Mark E. Flanagan, Zheng J. Li
-
Patent number: 6962993Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.Type: GrantFiled: June 16, 2003Date of Patent: November 8, 2005Assignee: Pfizer Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
-
Patent number: RE41783Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.Type: GrantFiled: October 13, 2009Date of Patent: September 28, 2010Assignee: Pfizer Inc.Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof